MedTrace Logo

Detection of Germline and Somatic Pathogenic Variants in Patients With de Novo Metastatic Breast Cancer

NCT05758948 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 101

Last updated 2023-04-07

No results posted yet for this study

Summary

To determine somatic and germline pathogenic variants in patients with denovo metastatic breast cancer in order to map the molecular/genetic characteristics of DN- MBC aiming in comprehending the biology and highlighting potential novel treatment options for the disease.

Conditions

Interventions

DIAGNOSTIC_TEST

NGS in blood and Formalin-Fixed Paraffin-Embedded (FFPE) tissue

In patients with denovo metastatic breast cancer blood and tissue sample will be collected and then further analysed using NGS in order to detect somatic and germline pathogenic variants

Sponsors & Collaborators

  • Hellenic Society of Medical Oncology

    collaborator OTHER

  • Hellenic Cooperative Oncology Group

    lead OTHER

Principal Investigators

  • EVANGELIA MOIROGIORGOU · YGEIA Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-07-05
Primary Completion
2010-10-05
Completion
2023-06-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05758948 on ClinicalTrials.gov